TY - JOUR
T1 - Emerging drugs for high-grade osteosarcoma
AU - Hattinger, Claudia Maria
AU - Pasello, Michela
AU - Ferrari, Stefano
AU - Picci, Piero
AU - Serra, Massimo
PY - 2010/12
Y1 - 2010/12
N2 - Importance of the field: Osteosarcoma (OS) is the most common primary malignant bone tumour in children and adolescents. This review focuses on the most promising therapeutic markers and drugs which may potentially be considered for innovative high-grade OS treatments. Areas covered in this review: The list of drugs and compounds reviewed has been generated by taking into account those which target markers of potential clinical interest for high-grade OS and have been included in Phase I, II or III clinical trials. The literature search covers the last 40 years, starting from the first OS chemotherapy reports of the early 1970s. Particular relevance was given to reports and reviews on new targeted therapies of possible clinical usefulness for high-grade OS. What the reader will gain: This review gives an updated overview of novel therapeutic approaches which have been or are going to be evaluated in Phase I/II/III clinical studies for high-grade OS. Take home message: On the basis of the information that has emerged so far, it can be predicted that in the next 5-10 years, new agents to be included in innovative treatment strategies for selected subgroups of high-grade OS patients may become available.
AB - Importance of the field: Osteosarcoma (OS) is the most common primary malignant bone tumour in children and adolescents. This review focuses on the most promising therapeutic markers and drugs which may potentially be considered for innovative high-grade OS treatments. Areas covered in this review: The list of drugs and compounds reviewed has been generated by taking into account those which target markers of potential clinical interest for high-grade OS and have been included in Phase I, II or III clinical trials. The literature search covers the last 40 years, starting from the first OS chemotherapy reports of the early 1970s. Particular relevance was given to reports and reviews on new targeted therapies of possible clinical usefulness for high-grade OS. What the reader will gain: This review gives an updated overview of novel therapeutic approaches which have been or are going to be evaluated in Phase I/II/III clinical studies for high-grade OS. Take home message: On the basis of the information that has emerged so far, it can be predicted that in the next 5-10 years, new agents to be included in innovative treatment strategies for selected subgroups of high-grade OS patients may become available.
KW - drug resistance
KW - osteosarcoma
KW - tailored therapy
KW - target-specific drugs
KW - therapeutic markers
UR - http://www.scopus.com/inward/record.url?scp=78649460883&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649460883&partnerID=8YFLogxK
U2 - 10.1517/14728214.2010.505603
DO - 10.1517/14728214.2010.505603
M3 - Article
C2 - 20690888
AN - SCOPUS:78649460883
SN - 1472-8214
VL - 15
SP - 615
EP - 634
JO - Expert Opinion on Emerging Drugs
JF - Expert Opinion on Emerging Drugs
IS - 4
ER -